Second Sight Medical Products (EYES) Stock Price, News & Analysis

Company Overview

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $4.11 to $13.05
• 52-Week Range: N/A
• Volume: 36,800 shs
• Average Volume: 132,982 shs
• Market Capitalization: $54.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EYES Stock Analysis - Frequently Asked Questions

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) released its quarterly earnings data on Monday, June, 29th. The medical device company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($1.23) by $0.48.

When did Second Sight Medical Products' stock split?

Second Sight Medical Products's stock reverse split on Friday, August 19th 2022.The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

When did Second Sight Medical Products IPO?

Second Sight Medical Products (EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Canopy Growth (CGC) and

Company Calendar

• Last Earnings: 6/29/2020
• Today: 10/20/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Electromedical Equipment
• Sub-Industry: N/A
• Current Symbol: NASDAQ:EYES
• CIK: 1266806
• Web: www.secondsight.com
• Phone: (818) 833-5000
• Fax: 818-833-5067
• Employees: 15
• Year Founded: 1998

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.92 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -13.58%
• Return on Assets: -13.02%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 22.15
• Quick Ratio: 22.15

Sales & Book Value

• Annual Sales: $3.38 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.80 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 13,135,000
• Free Float: 6,935,000
• Market Cap: $54.38 million
• Optionable: Optionable
• Beta: 2.55